1.Why was HanchorBio founded? 2.When was HanchorBio established, and what is its founding mission?3. What research achievements or fundraising successes has HanchorBio accomplished so far? 4.What is HanchorBio’s vision? 5.In the fields of biotechnology and healthcare, what contributions can HanchorBio make to society? 6.What are the key differences and advantages between HanchorBio’s drug candidates and traditional therapies? What is the core technology? 7.What is FBDB™? What makes it special, and how does it support research and development? 8.What is the expected scale or extent of the beneficiaries? For such multi-target biologics designed to reactivate the immune system against diseases, can this mechanism be applied to other diseases or medical fields?

HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the US. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.

HanchorBio Inc. completed a face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023, in Taipei, Taiwan withworld-renowned professors and few Board of Director (BOD) members.

HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-medicines, completed a face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023 in Taipei, Taiwan with world-renowned professors and few Board of Director (BOD) members.

Dr. Liu was awarded on November 12, 2022, as part of the CABS 23rd Annual BioPacific Conference entitled, “Resilience and Ingenuity – Embracing Opportunities in a New Normal”. The theme this year reflects economic and supply chain turbulences that have presented both new challenges and opportunities for the life sciences and biopharmaceutical industries, despite ongoing COVID-19. For the past 24 years, CABS has been one of the largest and most active non-profit biopharmaceutical organizations in western United States.

At the SAPA conference, HanchorBio presented the company’s proprietary Fc-based designer biologics (FBDB™) platform led to biological products that targeting phagocytosis checkpoint blockade and incorporating both innate and adaptive immune responses to treat patients with cancer. During the conference, HanchorBio ended with dozens of one-on-one meetings with national and international partners and multiple possible leads for in-licensing, research collaborations, or commercial right out-licensing conducted by Dr. Yi Du (Sr. Director of Business Development). These discussions mainly focused on advancing science and innovation on the development of anti-tumor immunotherapies to eliminate tumor immune escape.

August 5th, 2022 – HanchorBio Inc. (“HanchorBio”), a biotechnology company pioneering the development of next-generation immunotherapies, today announced the successful completion of approximately US$20 million Series-A financing. The proceeds will enable HanchorBio to further expand and accelerate its growing pipeline of the proprietary Fc-based designer biologics (FBDB™) and to support the anticipated investigational new drug (IND)-enabling good laboratory practice (GLP) toxicology studies, IND submissions, and the first part of phase 1 clinical trials.